Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H14NO |
| Molecular Weight | 140.2029 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CC1=CC=CO1
InChI
InChIKey=HEDXEAAVEOJUCR-UHFFFAOYSA-N
InChI=1S/C8H14NO/c1-9(2,3)7-8-5-4-6-10-8/h4-6H,7H2,1-3H3/q+1
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
10 % 1 times / day multiple, ophthalmic Dose: 10 %, 1 times / day Route: ophthalmic Route: multiple Dose: 10 %, 1 times / day Sources: |
unhealthy |
Disc. AE: Dacryostenosis acquired... AEs leading to discontinuation/dose reduction: Dacryostenosis acquired (71%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Dacryostenosis acquired | 71% Disc. AE |
10 % 1 times / day multiple, ophthalmic Dose: 10 %, 1 times / day Route: ophthalmic Route: multiple Dose: 10 %, 1 times / day Sources: |
unhealthy |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. | 1997-07 |
|
| Glaucoma treatment by furnethide and diisopropylfluorophosphate. | 1949-07 |
|
| The use of furmethide in comparison with pilocarpine and eserine for the treatment of glaucoma. | 1947-08 |
|
| Further studies on the use of furmethide in the treatment of glaucoma. | 1946-04 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C47792
Created by
admin on Mon Mar 31 17:59:14 GMT 2025 , Edited by admin on Mon Mar 31 17:59:14 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
10938
Created by
admin on Mon Mar 31 17:59:14 GMT 2025 , Edited by admin on Mon Mar 31 17:59:14 GMT 2025
|
PRIMARY | |||
|
7618-86-2
Created by
admin on Mon Mar 31 17:59:14 GMT 2025 , Edited by admin on Mon Mar 31 17:59:14 GMT 2025
|
PRIMARY | |||
|
DTXSID50227048
Created by
admin on Mon Mar 31 17:59:14 GMT 2025 , Edited by admin on Mon Mar 31 17:59:14 GMT 2025
|
PRIMARY | |||
|
AIQ630U6XO
Created by
admin on Mon Mar 31 17:59:14 GMT 2025 , Edited by admin on Mon Mar 31 17:59:14 GMT 2025
|
PRIMARY | |||
|
C028530
Created by
admin on Mon Mar 31 17:59:14 GMT 2025 , Edited by admin on Mon Mar 31 17:59:14 GMT 2025
|
PRIMARY | |||
|
m5611
Created by
admin on Mon Mar 31 17:59:14 GMT 2025 , Edited by admin on Mon Mar 31 17:59:14 GMT 2025
|
PRIMARY | Merck Index | ||
|
C72790
Created by
admin on Mon Mar 31 17:59:14 GMT 2025 , Edited by admin on Mon Mar 31 17:59:14 GMT 2025
|
PRIMARY | |||
|
3256
Created by
admin on Mon Mar 31 17:59:14 GMT 2025 , Edited by admin on Mon Mar 31 17:59:14 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
